PolyPeptide Group AG/Fr. PPGN
08:00
10:05
12:10
14:15
16:20
1D1W1MYTD1Y5YMAX
About PolyPeptide Group AG
PolyPeptide Group AG operates in the pharmaceutical industry, specializing in the development and manufacture of peptides for various applications. Headquartered in Zug, Switzerland, the company provides essential services and products for the pharmaceutical and biotechnology sectors, including custom peptide synthesis and generic peptide production. With a network of manufacturing facilities across Europe and the United States, PolyPeptide Group AG supports a global clientele. The company's strategic positioning is reinforced by its focus on innovation and quality, ensuring compliance with rigorous industry standards. PolyPeptide's competitive strength lies in its extensive expertise and capabilities in peptide synthesis, serving sectors ranging from therapeutic peptides to cosmetics.
Ticker
Fr. PPGN
Sector
Primary listing
XSWX
Employees
1,400
Headquarters
Baar, Switzerland
Website
PPGN Metrics
BasicAdvanced
CHF 802M
-
-CHF 0.94
1.13
-
Price and volume
Market cap
CHF 802M
Beta
1.13
52-week high
CHF 32.70
52-week low
CHF 13.22
Average daily volume
62K
Financial strength
Current ratio
1.624
Quick ratio
0.729
Long term debt to equity
31.672
Total debt to equity
33.632
Interest coverage (TTM)
-0.23%
Profitability
EBITDA (TTM)
17.925
Gross margin (TTM)
11.26%
Net profit margin (TTM)
-9.41%
Operating margin (TTM)
-1.93%
Effective tax rate (TTM)
5.89%
Revenue per employee (TTM)
CHF 234,890
Management effectiveness
Return on assets (TTM)
-0.62%
Return on equity (TTM)
-10.05%
Valuation
Price to revenue (TTM)
2.398
Price to book
2.42
Price to tangible book (TTM)
2.53
Price to free cash flow (TTM)
27.466
Free cash flow yield (TTM)
3.64%
Free cash flow per share (TTM)
0.874
Growth
Revenue change (TTM)
13.99%
Earnings per share change (TTM)
19.48%
3-year revenue growth (CAGR)
9.54%
3-year earnings per share growth (CAGR)
1.62%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PolyPeptide Group AG stock?
PolyPeptide Group AG (PPGN) has a market cap of Fr.802M as of March 17, 2026.
What is the P/E ratio for PolyPeptide Group AG stock?
The price to earnings (P/E) ratio for PolyPeptide Group AG (PPGN) stock is 0 as of March 17, 2026.
Does PolyPeptide Group AG stock pay dividends?
No, PolyPeptide Group AG (PPGN) stock does not pay dividends to its shareholders as of March 17, 2026.
When is the next PolyPeptide Group AG dividend payment date?
PolyPeptide Group AG (PPGN) stock does not pay dividends to its shareholders.
What is the beta indicator for PolyPeptide Group AG?
PolyPeptide Group AG (PPGN) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.